German investment bank Berenberg has upgraded specialty chemicals maker Evonik to “hold” from a previous negative stance and raised its price target to €20 per share, following reports that rival BASF has held early-stage takeover talks. The move signals that investors may be starting to price in a possible acquisition, even as the company's underlying business faces pressure in some key product lines.
Why Berenberg changed its view
Berenberg had been cautious on Evonik because parts of its portfolio, particularly methionine—an amino acid used as a feed additive for livestock—have been squeezed as the product becomes more commoditized. That has weighed on pricing power and margins.
However, the bank now says recent price relief linked to disrupted Asian feedstocks has bought the company some time, even though methionine prices have been slipping again. The bigger shift, according to Berenberg, is about valuation rather than chemistry.
In a note released Monday, Berenberg said BASF's interest could put a floor under Evonik's share price. The bank expects BASF to return with an offer in the range of €24 to €25 per share, after Evonik reportedly rejected an initial proposal of €22.15. Berenberg added that a price of €25.3 per share would value Evonik at about eight times its expected 2027 earnings before interest, taxes, depreciation, and amortization (EBITDA)—a common cash-profit proxy—roughly in line with BASF's own valuation.
Forecast cuts vs. deal potential
Even with the upgrade, Berenberg trimmed its earnings-per-share forecasts for 2026-2028 and cut its sales and operating profit estimates. That might seem contradictory, but the bank's logic is that a credible bid range can matter more for the stock than near-term forecast cuts. When a takeover looks plausible, investors start weighing the potential “deal price” against the company's “standalone value” as headlines shift the odds.
This is a common dynamic in M&A situations. Once a bid is on the table—or even rumored—the stock often trades less on quarterly revisions and more on the “deal spread,” which is the gap between the current market price and a possible offer price. That gap reflects the market's perceived probability that a deal will happen. If investors believe BASF could come back near the €24-25 range Berenberg outlined, that can lift the implied downside floor, even while analysts lower their earnings estimates.
What it means for investors
For everyday investors, the key takeaway is that Evonik's share price may now be “pinned” between two reference points: Berenberg's €20 price target, which represents a standalone valuation, and the potential bid zone of €24-25. The biggest moves in the stock are likely to come from signals about whether the talks are warming up or cooling down, rather than from routine earnings updates.
That said, it's important to remember that takeover talks are often speculative and can fall through. Even if BASF is interested, there's no guarantee a deal will be reached, or that the terms will match Berenberg's expectations. Investors should treat such reports as one factor among many, not as a certainty.
For context, Evonik is a major player in specialty chemicals, with products ranging from coatings and additives to health and nutrition ingredients. BASF, one of the world's largest chemical companies, has been looking to streamline its own portfolio, and a move for Evonik would be a significant consolidation in the sector.
Elsewhere in markets, miners have helped steady the FTSE 100 as gold and silver prices climb, while corporate bond prices have slipped as borrowing surges and US hiring cools. These are reminders that a range of forces—from commodity prices to central bank policy—can influence investor sentiment.
Looking ahead
Investors will be watching for any official confirmation from BASF or Evonik regarding the talks. Until then, the stock is likely to remain sensitive to headlines. For those holding Evonik shares, the Berenberg note offers a more constructive view, but the situation remains fluid.
As always, it's wise to consider the broader picture. Takeover speculation can create short-term volatility, but long-term value depends on the company's fundamentals and the eventual outcome of any negotiations. For now, the market seems to be betting that a bid is possible—and that alone may be enough to keep a floor under the shares.
